CollPlant Biotechnologies Ltd.
CLGN
NASDAQ·Healthcare·Biotechnology·Mkt cap $4.5M
$3.41
▼ -1.45%
P/E
-1.29
Mkt Cap
$4.5M
52-Wk Range
$2.64–$26.80
52-Week Range
$2.64 - $26.80
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 85.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary plant-based recombinant collagen production technology with superior biocompatibility
- Diversified product portfolio spanning aesthetics, wound care, and regenerative medicine reducing market concentration risk
- Strategic partnerships with industry leaders (3D Systems, AbbVie, STEMCELL, Technion) providing validation and distribution channels
- First-mover advantage in 3D bioprinted medical devices with established IP protection and regulatory pathways
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Rising global demand for advanced wound care solutions, particularly for chronic and diabetic ulcers
Value
Valuation data unavailable
Momentum
Weak
-19.2% over 3m
Quality
Loss-making
Weak fundamentals - proceed with caution
Dividend
None
No dividend
Smart-money signal
Who's buying CLGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Dec 2, 2026
SEP 30, 2026
Reported EPS of -$1.89 vs -$2.45 consensus (+22.9% surprise). Revenue of $108.0K vs $480.0K expected (-77.5%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+22.9%
Revenue trend · last 8Q
—
—
—
-28%
-69%
-63%
-96%
-40%
Q2 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$249.0K
$164.0K
$2.1M
$179.0K
$77.0K
$60.0K
$73.0K
$108.0K
Margins · last 8Q
Gross
—
Operating
—
Profit
-2524.1%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CLGN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related